Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 36Carcinoma, Non-Small-Cell Lung 17Small Cell Lung Carcinoma 16Neoplasms 14Lung Neoplasms 13Breast Neoplasms 8Melanoma 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Glioblastoma 4Endometrial Neoplasms 4Recurrence 3Ovarian Neoplasms 3Neoplasms by Site 3Neoplasms by Histologic Type 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Osteosarcoma 2Mesothelioma, Malignant 2Mesothelioma 2

Interventions

pembrolizumab 3Temozolomide 3Specimen Handling 3Radiotherapy 2peposertib 1liposomal doxorubicin 1gosha-jinki-gan 1efineptakin alfa 1cabozantinib 1balstilimab 1atezolizumab 1abexinostat 1Surgical Procedures, Operative 1Radiation 1ONC206 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gliosarcoma × atezolizumab × Clear all
NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
6 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡